CANSINOBIO (06185.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec19

CanSino Biologics Starts I Phase Clinical Trial for DTcP-Hib-MCV4 Combination Vaccine

08:35

CanSino Biologics Starts Phase I Clinical Trials for Tetra-valent Vaccine

08:09

CanSino's Sci-Tech board listing boosts vaccine industrialization

04:52

Nov17

CanSino Continues to Enhance Market Penetration of Quadrivalent Meningococcal Conjugate Vaccine Menhison

11:51

Nov13

CanSino Initiates Phase I Clinical Trial for Intranasal Tuberculosis Vaccine in Indonesia with First Subject Enrollment

08:28

Nov7

CanSino Biologics Proposes to Use Surplus Reserve to Offset Accumulated Losses

08:40

Schedules & Filings

Schedules

Filings

Oct27

Earning Release(CST)

FY2025 Q3 Earning Release (HKD) Revenue 339.14 M, Net Income 30.53 M, EPS 0.1671

Aug20

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 268.34 M, Net Income -2.123 M, EPS -0.0068

Apr29

Earning Release(CST)

FY2025 Q1 Earning Release (HKD) Revenue 146.9 M, Net Income -12.36 M, EPS -0.0535

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change